Keenova Therapeutics plc: 10% owner GoldenTree bought 463,000 shares

What happened

• GoldenTree Asset Management LP, reported as a 10% owner, purchased 463,000 ordinary shares of Keenova Therapeutics plc on Sep 24, 2026, at $91.00 per share for $42,133,000. The transaction is reported on Form 4 as a purchase (transaction code P).

Key details

• Transaction date and price: Sep 24, 2026, at $91.00 per share; total reported cost $42,133,000.
• Filing date: Oct 6, 2026.
• Shares held as reported in the filing: 8,389,212 ordinary shares held directly by certain funds and separate accounts managed by the Advisor, and 53,615 ordinary shares held directly by Steven A. Tananbaum (as described in footnotes).
• Relevant footnotes: F1 describes reporting persons as the Advisor (GoldenTree Asset Management LP), the General Partner (GoldenTree Asset Management LLC) and Steven A. Tananbaum and their relationships to the Funds; F2 states the Advisor, the General Partner, and Mr. Tananbaum disclaim beneficial ownership of the Ordinary Shares held by the Funds; F3 notes Mr. Tananbaum may be deemed to have a pecuniary interest in the shares in which the Advisor and the General Partner have an interest.
• Transaction code: P (purchase).

Why it may matter

• The buyer is reported as a 10% owner, i.e., a large holder rather than an executive officer.
• This was a market or private purchase reported as such on Form 4.
• A filing does not show why the insider traded or why the company acted.